Dual-ligand cantharidin nanoparticles show promise for hepatocellular carcinoma treatment
Dual-ligand-modified cantharidin nanoparticles demonstrated a 58.67% tumor inhibition rate in Huh-7 tumor-bearing mice, with enhanced safety profiles.
Asset / Drug
Drug and asset intelligence for sorafenib with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.